On a much higher than reported incidence of anti-c in R1R1 patients with anti-E

Publications

Share / Export Citation / Email / Print / Text size:

Immunohematology

American National Red Cross

Subject: Medical Laboratory Technology

GET ALERTS SUBSCRIBE

ISSN: 0894-203X
eISSN: 1930-3955

DESCRIPTION

4
Reader(s)
4
Visit(s)
0
Comment(s)
0
Share(s)

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue / page

Archive
Volume 37 (2021)
Volume 36 (2020)
Volume 35 (2019)
Volume 34 (2018)
Volume 33 (2017)
Volume 32 (2016)
Volume 31 (2015)
Volume 30 (2014)
Volume 29 (2013)
Volume 28 (2012)
Volume 27 (2011)
Volume 26 (2010)
Volume 25 (2009)
Volume 24 (2008)
Volume 23 (2007)
Volume 22 (2006)
Volume 21 (2005)
Volume 20 (2004)
Volume 19 (2003)
Volume 18 (2002)
Volume 17 (2001)
Volume 16 (2000)
Volume 15 (1999)
Volume 14 (1998)
Volume 13 (1997)
Volume 12 (1996)
Volume 11 (1995)
Volume 10 (1994)
Volume 9 (1993)
Volume 8 (1992)
Volume 7 (1991)
Volume 6 (1990)
Volume 5 (1989)
Volume 4 (1988)
Volume 3 (1987)
Related articles

VOLUME 21 , ISSUE 3 (September 2005) > List of articles

On a much higher than reported incidence of anti-c in R1R1 patients with anti-E

W. John Judd / Louann R. Dake / Robertson D. Davenport

Keywords : anti-c, anti-E

Citation Information : Immunohematology. Volume 21, Issue 3, Pages 94-96, DOI: https://doi.org/10.21307/immunohematology-2019-399

License : (Transfer of Copyright)

Published Online: 27-April-2020

ARTICLE

ABSTRACT

A previous study involving tube IATs, untreated RBCs, and a lowionic-strength additive reagent revealed that approximately onethird of R1R1 patients with anti-E have a concomitant anti-c. However,the current study finds a much higher incidence of anti-c in such patients, using gel technology in conjunction with ficinpretreated RBCs. Results of antibody identification studies and transfusion records of 82 R1R1 patients with anti-E were reviewed. Serologic test methods included a LISS wash solution for tube IATs (15 min at 37°C,anti-IgG),ficin-tube IATs (30 min at 37°C,anti-IgG + anti-C3), and gel IATs (untreated or ficin-treated RBCs or both, anti-IgG gels). LISS-tube or gel IATs with untreated RBCs revealed anti-c in 32 patients with anti-E. When gel-IAT and ficin-pretreated RBCs were used, 21 additional patients with anti-E were found to have anti-c. In samples from 26 R1R1 patients with anti-E,anti-c was not demonstrable by ficin-gel IATs,and in 3 cases,the ficin-gel tests were inconclusive. In five cases in which E– RBCs not tested for c antigen were transfused to patients found by ficin-gel IAT to be without anti-c,all subsequently performed crossmatches with E–,cuntested RBCs were compatible. The incidence of anti-c in R1R1 patients with anti-E in this study was 32 of 82 (39%) with untreated RBCs and 53 of 82 (65%) when the ficin gel data were included. The latter is significantly higher than the 32 percent incidence previously reported (p = 0.0001). Accordingly, all patients at our facility with an Rh antibody are now tested for those additional Rh antibodies they can make, as predicted from their Rh phenotype. The data from this study strongly support the selection of R1R1 RBCs for all c– patients with anti-E.

You don't have 'Full Text' access of this article.

Purchase Article Subscribe Journal Share